AgelessRx Launches Three New Peptides, Guided by the AgelessRx Peptide Standard

New injectable peptide plans bring some of longevity’s most talked-about peptides into clinician-guided care, with ongoing clinical oversight.

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, the first-of-its-kind longevity care platform bringing the latest in longevity science into everyday care, today announced the launch of clinician-guided injectable peptide plans for BPC-157, TB-500, and MOTS-c.

BPC-157 is a synthetic peptide based on a compound found naturally in the stomach. Researchers are studying its potential role in tissue repair, recovery, and inflammatory signals, though most research is preliminary, with limited studies in people.

TB-500 is a synthetic fragment of thymosin beta-4, a peptide the body makes that helps cells move and tissues repair. Researchers are exploring whether it may support recovery of tendons, ligaments, and muscle, though most of the evidence comes from thymosin beta-4, with limited direct human research on TB-500 itself.

MOTS-c is a peptide the body makes from mitochondrial DNA, the genetic material in the parts of a cell that make energy. Researchers are studying its potential role in metabolism, insulin sensitivity, and healthy aging, though most of the evidence is still early.

A licensed medical provider reviews each person’s health history, medications, and goals to decide whether a peptide is appropriate, with ongoing clinical support throughout care.

“Peptides are one of the most exciting areas in longevity, and some of these have real promise, but the honest truth is that the human evidence is still thin,” said Anar Isman, CEO and Co-Founder of AgelessRx. “We’d rather say that plainly than oversell them. We’re offering them with a clinician guiding every plan, and we’ll be watching the clinical data closely to learn which ones truly help people live longer, healthier lives. This is a journey we’re taking together with our members, and we’re investing in the research, including studies with the members who want to be part of it, to get to the truth.”

In July, an FDA advisory committee reviewed seven peptides for possible inclusion on the 503A Bulks List, the list of ingredients licensed pharmacies can use in compounding. On October 30, 2026, the FDA issued an interim policy draft stating that it does not currently intend to take enforcement action against licensed compounding pharmacies that prepare six of those peptides, including BPC-157, TB-500, and MOTS-c, while the agency completes its review. The interim policy is not an FDA approval. It does not mean the FDA has found these peptides to be safe or effective, and it may change.

AgelessRx evaluates every peptide it considers under the AgelessRx Peptide Standard, a public framework that weighs the evidence for each peptide and the sourcing, quality, transparency, and clinical accountability of the company offering it. AgelessRx also applies the Standard to itself through third-party scoring and publishes its own assessment. The full Standard is available at agelessrx.com/agelessrx-peptide-standard/.

“Peptides are moving fast, and that makes it important to be selective,” said Stefanie Morgan, PhD, Vice President, Operations and Applied Science at AgelessRx. “Our team has been following the science on these closely, and we’re excited to see them reach members with clinicians guiding care. We are currently designing the largest trial yet on BPC-157 and the first-ever TB-500 trial. We’re looking forward to sharing what we learn.”

BPC-157, TB-500, and MOTS-c join AgelessRx’s growing peptide lineup, which includes Sermorelin, PT-141, and GHK-Cu Cream.

AgelessRx has invested early in building longevity expertise, including fully in-house Clinical and Care teams and a Stanford PhD-led Research Team. Its researchers have conducted more than 11 in-house longevity clinical trials and published nine peer-reviewed papers, while its clinicians bring more than 199 years of combined clinical experience.

In August 2026, AgelessRx was named a Top 10 Milestone 2 Awardee in the $101 million XPRIZE Healthspan competition, standing out among more than 600 competing teams. The competition challenges teams to reverse age-related decline in muscle, cognitive, and immune function.

BPC-157, TB-500, and MOTS-c are compounded medications and are not FDA-approved. The FDA has not reviewed these statements or approved these compounded products for any use, or for safety, efficacy, or quality.

BPC-157, TB-500, and MOTS-c are available now to eligible adults following review by a licensed medical provider.

To learn more, visit agelessrx.com/peptides.

About AgelessRx

AgelessRx is helping redefine how people age, combining clinically validated treatments with cutting-edge longevity science to support longer, healthier lives. The company advances the field through ongoing research and clinical trials while making proactive, evidence-informed care more accessible through its online platform. Follow AgelessRx on Instagram, TikTok, X, and Facebook.